Episode
Reprogramming T Cells to Cross the Brain’s Border
- Podcast
- The Bio Report
- Published
- Feb 4, 2026
- Duration seconds
- 2327
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-bio-report-1092382/episodes/reprogramming-t-cells-to-cross-the-brain-s-border/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-bio-report-1092382/reprogramming-t-cells-to-cross-the-brain-s-border.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
One of the challenges of treating brain tumors is delivering potent biologic therapies across the blood-brain barrier. Adaptin Bio has developed platform technology that harnesses a patient’s own T cells to transport bispecific therapeutic payloads across the blood-brain barrier and into other targeted tissue with an initial focus on treating glioblastoma. We spoke to Michael Roberts, co-founder and CEO of Adaptin Bio, about the unmet need in glioblastoma, the limitations of current blood-brain barrier–crossing strategies, and how the company’s platform seeks to change the treatment paradigm by using patient-derived T cells as delivery vehicles for targeted biologics.